(1 - 13 from 32
)
BI submits marketing application for tiotropium/olodaterol Respimat...
www.oindpnews.com
BI Chief Medical Officer Klaus Dugi commented, “The fixed-dose combination of tiotropium and olodaterol represents another major advance ...
Boehringer drug approved in EU for rare lung disease - PMLiVE
www.pmlive.com
Boehringer's chief medical officer Prof Klaus Dugi said: “This approval is another milestone in Boehringer Ingelheim's ongoing efforts with ...
Boehringer’s Vargatef approved in the EU for lung cancer - PMLiVE
www.pmlive.com
Prof Klaus Dugi, Boehringer's chief medical officer, said: “The approval of Vargatef expands our oncology portfolio, following last year's ...
Boehringer gets fresh FDA approval for Pradaxa - PharmaTimeswww.pharmatimes.com › news › boehringer_gets_fresh_f...
www.pharmatimes.com
Boehringer chief medical officer Klaus Dugi said the approval of these new indications "represents another significant landmark for Pradaxa ...
sorted by relevance / date